The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis
Christopher E Starr,1 Kelly K Nichols,2 Jacob R Lang,3 Todd C Brady4 1Department of Ophthalmology, Weill Cornell Medicine, New York, NY, USA; 2School of Optometry, University of Alabama, Birmingham, AL, USA; 3College of Optometry, the Ohio State University, Columbus, OH, USA; 4Aldeyra Therapeutics,...
Main Authors: | Starr CE, Nichols KK, Lang JR, Brady TC |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-12-01
|
Series: | Clinical Ophthalmology |
Subjects: | |
Online Access: | https://www.dovepress.com/the-phase-3-invigorate-trial-of-reproxalap-in-patients-with-seasonal-a-peer-reviewed-fulltext-article-OPTH |
Similar Items
-
Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure
by: Clark D, et al.
Published: (2022-01-01) -
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
by: McLaurin E, et al.
Published: (2017-06-01) -
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
by: Malhotra RP, et al.
Published: (2019-02-01) -
Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
by: Meier EJ, et al.
Published: (2018-12-01) -
Validation of the DECA criteria for allergic conjunctivitis severity and control
by: M. Cesárea Sánchez-Hernández, et al.
Published: (2020-10-01)